TGBA01AD (also known as FKB01MD) is a
serotonin reuptake inhibitor
A serotonin reuptake inhibitor (SRI) is a type of drug which acts as a reuptake inhibitor of the neurotransmitter serotonin (5-hydroxytryptamine, or 5-HT) by blocking the action of the serotonin transporter (SERT). This in turn leads to incre ...
,
5-HT1A and
5-HT1D receptor agonist, and
5-HT2 receptor antagonist which is under development by
Fabre-Kramer for the treatment of
major depressive disorder
Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Intro ...
.
It has been in
phase II clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...
s since 2009, and as of January 2016, remains in this phase of development.
See also
*
List of investigational antidepressants
This is a list of investigational antidepressants, or antidepressants that are currently under development for clinical use in the treatment of mood disorders but are not yet approved. ''Chemical/generic names are listed first, with developmental ...
References
5-HT1A agonists
5-HT1D agonists
5-HT2 antagonists
Antidepressants
Drugs with undisclosed chemical structures
Serotonin reuptake inhibitors
{{Nervous-system-drug-stub